Neuralink N1 implant
Trials ongoing

Stop seizures
before they spread.

Neurosurgery has spent decades removing things.
For the first time, we're looking to add something back.

See the Chip View Animal Studies
The problem
65M
people live with epilepsy worldwide
1 in 3
find no relief from any drug ever made
$30B
in annual economic burden in the U.S. alone
Simulated neural activity

Research prototype

Meet neuræ™
a neural processing layer.

Configurable, physician-monitored closed-loop neuromodulation for drug-resistant epilepsy. Built to detect, predict, and arrest seizures in real time, entirely on-device. Our rodent pipeline demonstrates a median 62% seizure reduction at 3-month treatment.

neurae chips on wafer tray
neurae single die under microscope

Final verifications
Yale School of Medicine
Rat with cortical implant - MD-Eid#4b

Meet our
first patient!

Validated at Yale School of Medicine using a custom closed-loop recording and stimulation toolchain. We are now moving to primate studies.


The Evidence

Why other approaches fall short. Why intervention saves lives.

Despite 40 years and 30+ drugs, the 1-in-3 drug-resistant rate has not moved. New drugs like cenobamate help some patients, but a large persistent population remains unreachable by pharmacology alone. Non-invasive technologies like focused ultrasound are promising but remain in Phase I trials with no FDA approval for epilepsy. For this population, closed-loop implantable neuromodulation is the only evidence-backed solution available today.

Pharmacology

Drugs have hit a ceiling

Despite approximately 30 licensed anti-seizure medications, the proportion of drug-resistant patients has remained at 30–40% since 1982. New drugs treat symptoms, not causes. Tolerance and cross-resistance mean the ceiling is structural, not incremental.

Kwan et al., JAMA Neurology 2018 ↗
Non-Invasive

Non-invasive tech is 10-15 years out. And it won't reach everyone.

Focused ultrasound (tFUS) is in Phase I safety trials today. Realistically, FDA approval for epilepsy is a decade away at minimum. More importantly, even an approved tFUS device will not serve the full drug-resistant population.

Premaratne et al., J. Neurology 2025 ↗
Implants

Implants work. They save lives.

Responsive neurostimulation and closed-loop DBS are FDA-approved and reduce seizures in patients who have exhausted all other options. For refractory epilepsy, implantable devices represent the last and most effective intervention available before irreversible outcomes set in.

NeuroPace RNS FDA Approval ↗

Tools provided

Request a Demo.

Book a demo and download our open-source hardware stack. Built for seizure treatment verification.

Intan RHX Recording Controller
Recording Software

Intan RHX

External provider via Intan SDK. Only required for real in-vivo testing.

Download
HALO Reading Controller
Analysis Software

Neuræ Reader

Not yet Apple certified. You may need to allow it in System Settings.

Download

Long-term goals
Yale BCI chip
Our Edge

We Build Reconfigurable Architecture.

We aim to research and design silicon and packaging solutions that shift from fixed-function to general-purpose architectures, tackling larger amounts of neural throughput under stringent FDA power constraints. Long-term, we are exploring the tapeout of small-parameter AI models directly onto neural silicon.


Yale-based research

Built different.
By design.

The only reconfigurable BCI with full on-chip compute
and closed-loop capability.

neuræ Medtronic NeuroPace Aziz Kassiri Neuralink NURIP Blackrock Synchron
Tasks Supported
Spike Detection
Compression
Seizure Prediction
Movement Intent
Encryption
Technical Capabilities
Programmable LimitedLimitedLimited
Read Channels 96 48256243072329616
Data Rate (Mbps) 46 0.010.029.761.325450.13300.5
Power (mW) 15 26.512820101510
Safety (<15 mW)
Architecture GALS FixedFixedFixedReconfig.FixedFixedFixedFixed
Processing
On-chip Processing Full LimitedLimitedLimitedLimitedLimited
Closed-loop

Ready to stop
the next seizure?

We're working with select neurology centers, research labs, and neurotech investors.